Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO(2)VATE trials

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are currently the mainstay of treatment for anaemia of chronic kidney disease (CKD). Vadadustat is an investigational oral hypoxia-inducible factor prolyl-hydroxylase inhibitor that stimulates endogenous erythropoietin formation. The INNO(2)VATE p...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckardt, Kai-Uwe, Agarwal, Rajiv, Farag, Youssef Mk, Jardine, Alan G, Khawaja, Zeeshan, Koury, Mark J, Luo, Wenli, Matsushita, Kunihiro, McCullough, Peter A, Parfrey, Patrick, Ross, Geoffrey, Sarnak, Mark J, Vargo, Dennis, Winkelmayer, Wolfgang C, Chertow, Glenn M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577631/
https://www.ncbi.nlm.nih.gov/pubmed/33188693
http://dx.doi.org/10.1093/ndt/gfaa204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577631/
https://www.ncbi.nlm.nih.gov/pubmed/33188693
http://dx.doi.org/10.1093/ndt/gfaa204

Ejemplares similares